Description: Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Home Page: www.cidara.com
CDTX Technical Analysis
6310 Nancy Ridge Drive
San Diego,
CA
92121
United States
Phone:
858 752 6170
Officers
| Name | Title |
|---|---|
| Dr. Jeffrey L. Stein Ph.D. | Pres, CEO & Exec. Director |
| Dr. Taylor Sandison | Chief Medical Officer |
| Dr. Les Tari Ph.D. | Chief Scientific Officer |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer |
| Dr. Preetam Shah M.B.A., Ph.D. | CFO, Chief Bus. Officer & Principal Accounting Officer |
| Mr. Shane M. Ward | COO & Chief Legal Officer |
| Ms. Allison Lewis CCP, SPHR | VP of HR |
| Mr. James M. Balkovec | Sr. VP of Research |
| Ms. Laura A. Navalta | Sr. VP of Clinical Operations |
| Ms. Carol Waldo | Sr. VP of Regulatory Affairs & Quality Assurance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.7854 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9486 |
| Price-to-Sales TTM: | 0.5691 |
| IPO Date: | 2015-04-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 89 |